But what makes it amazing is the investor deck and website will still say “in talks with fda on phase 3 approval”.

$EDSA Ruxolitinib (Opzelura) approved by FDA last year seems like a very solid drug for curing vitiligo and is generating tremendous revenue to Incyte.

FDA was pleased with their results and understands HC is moving forward.

* granted FDA fast track status late Dec 2022 * 75% of drugs given Fast Track get approved * ARDS current has limited treatment options, could make a big impact * CEO has sold two previous biotech companies to bigger players Let’s get it 😍🎊💥🆙✅

Fast Tracked FDA status on a drug with no competition.

It looks like EB05 is gonna be that home run, with FDA ‘Fast Track’ designation at the end of Dec 2022, we’re almost at the finish line.

FDA mulling over Emergency use right now I bet Holding strong. .

but to PR the positive review and approval They did exactly that with Fast Track, and also Compassionate Use BOTH APPROVED BY FDA!

$ACRX AcelRx has some GREAT EMA & FDA approved products, and I like the potential of Niyad!

$ACRX The FDA will be pleased with AcelRx "growing database supporting the benefits of DSUVIA-DZUVEO!

$IFRX we should get year end report late march if we have nothing from fda, ema or china we can only hope for cancer trial because pg is 2 years and an offering(s) away I’m a bull with alot of shares

$IFRX FDA approve now..vilo works and is safe!

Many options, FDA, NMPA and EMA. 🚀🚀🚀🤞🤞

I like Ifx-1’s chances of fda approval.

FDA approval please🤞

$IFRX nice to see us finally moving an extra 2.5 mil is nice should have our cash at least 93 mil with no debt with ema approval we will tap those final funds from german government and fda approval should hopefully send us into orbit

$IFRX Deutschland, EMA, FDA, CFDA, one must approve now, it is clearly evident humanity needs IFX-1 today!